Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Cancer and Metastasis Reviews

Volumn 34, Issue 4, 2015, Pages 797-805

  Toyokawa, Gouji ^a   Seto, Takashi ^a   Takenoyama, Mitsuhiro ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

ALK inhibitors; Anaplastic lymphoma kinase (ALK); Brain metastasis; Non small cell lung cancer

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; AP 26133; CERITINIB; CRIZOTINIB; LORLATINIB; UNCLASSIFIED DRUG; 7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; ANTINEOPLASTIC AGENT; BRIGATINIB; CARBAZOLE DERIVATIVE; MACROCYCLIC LACTAM; ORGANOPHOSPHORUS COMPOUND; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER INCIDENCE; CANCER PATIENT; DISEASE COURSE; DRUG EFFICACY; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84958870183     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9592-y     Document Type: Article

References (62)

1. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561–566.
2. Gainor, J. F., Varghese, A. M., Ou, S. H., Kabraji, S., Awad, M. M., Katayama, R., et al. (2013). ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical Cancer Research, 19(15), 4273–4281.
3. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine, 363(18), 1693–1703.
4. Camidge, D. R., Bang, Y. J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., et al. (2012). Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet Oncology, 13(10), 1011–1019.
5. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M. J., et al. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine, 368(25), 2385–2394.
6. Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhali, T., et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371(23), 2167–2177.
7. Seto, T., Kiura, K., Nishio, M., Nakagawa, K., Maemondo, M., Inoue, A., et al. (2013). CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. The Lancet Oncology, 14(7), 590–598.
8. Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, H. L., et al. (2014). Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding proportion of a phase 1/2 study. The Lancet Oncology, 15(10), 1119–1128.
9. Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., et al. (2014). Ceritinib for ALK-rearranged non-small-cell lung cancer. The New England Journal of Medicine, 370(13), 1189–1197.
10. Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004). Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 22(14), 2865–2872.
11. Schouten, L. J., Rutten, J., Huveneers, H. A., & Twijnstra, A. (2002). Incidence of brain metastases in a cohort of carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer, 94(10), 2698–2705.
12. Arrieta, O., Saavedera-Perez, D., Kuri, R., Aviles-Salas, A., Martinez, L., Mendoza-Posada, D., et al. (2009). Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer. doi:10.1186/1471-2407-9-119.
13. Hanna, N. H., Dahlberg, S. E., Kolesar, J. M., Aggarwal, C., Hirsch, F. R., Ramalingam, S. S., et al. (2015). Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonsmall cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: an Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. doi:10.1002/cncr.29308.
14. Doebele, R. C., Lu, X., Sumey, C., Maxson, D. A., Weickhardt, A. J., Oton, A. B., et al. (2012). Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. Cancer, 118(18), 4502–4511.
15. Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E., Mahadevan, A., Floyd, S. T., et al. (2015). Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer, 88(1), 108–111.
16. Felip, E., Orlov, S., Park, K., Yu, CJ., Tsai, CM., Nishio, M., et al. (2015). ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol, 33(supple; abstr 8060).
17. Shaw, A., Mehra, R., Tan, D., Felip, E., Chow, L. Q., Camidge, D. R., et al. (2014). Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study. Annals of Oncology, 2(4), iv426–iv470. doi:10.1093/annonc/mdu349.
18. Mok, T., Spigel, D., Felip, E., Ahn, MJ., Groen, MJA., Wakelee, HA., et al. (2015). ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol, 33(supple; abstr 8059).
19. Ou, SH., Ahn, JS., Petris, LD., Govindan, R., Yang, JCH., Hughes, BGM., et al. (2015). Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol, 33(supple; abstr 8008).
20. Gandhi, L., Shaw, A., Gadgeel, SM., Riely, G., Cetnar, J., West, HJ., et al. (2015). A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol, 33(supple; abstr 8019).
21. Camidge, DR., Bazhenova, L., Salgia, R., Langer, CJ., Gold, KA., Rosell, R., et al. (2015). Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol, 33(supple; abstr 8062).
22. Costa, D. B., Shaw, A. T., Ou, S. H., Solomon, B. J., Riely, G. J., Ahn, M. J., et al. (2015). Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. Journal of Clinical Oncology, 33(17), 1881–1888.
23. Ajimizu, H., Kim, Y. H., & Mishima, M. (2015). Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Medical Oncology, 32(2), 477.
24. Ou, S. H., Sommers, K. R., Azada, M. C., Garon, E. B., et al. (2015). Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. The Oncologist, 20(2), 224–226.
25. Gainor, J. F., Sherman, C. A., Willoughby, K., Logan, J., Kennedy, E., Brastianos, P. K., et al. (2015). Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. Journal of Thoracic Oncology, 10(2), 232–236.
26. Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., & Sakamoto, H. (2014). Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemotherapy and Pharmacology, 74(5), 1023–1028.
27. Nanjo, S., Nakagawa, T., Takeuchi, S., Kita, K., Fukuda, K., Nakada, M., et al. (2015). In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Science, 106(3), 244–252.
28. Shaw, AT., Bauer, TM., Felip, E., Besse, B., James, LP., Clancy, JS., et al. (2015). Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol, 33(supple; abstr 8018).
29. Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., et al. (2012). Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology, 30(4), 419–25.
30. Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., et al. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 14(4), 439–449.
31. Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Jr., et al. (2012). Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Journal of Thoracic Oncology, 7(12), 1807–1814.
32. Nieder, C., Grosu, A. L., Astner, S., Thamm, R., & Molls, M. (2006). Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Radiation Oncology, 1, 19.
33. Sekine, A., Satoh, H., Iwasawa, T., Tamura, K., Hayashihara, K., Saito, T., et al. (2014). Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Medical Oncology. doi:10.1007/s12032-014-0228-9.
34. Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., et al. (2012). Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy Pharmacology, 70(2012), 399–405.
35. Omuro, A. M., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N., Milton, D., et al. (2005). High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer, 103(11), 2344–2348.
36. Iuchi, T., Shingyouji, M., Sakaida, T., Hatano, K., Nagano, O., Itakura, M., et al. (2013). Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer, 82(2), 282–287.
37. Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., et al. (2012). The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer. Clinical Cancer Research, 18(16), 4406–4414.
38. Park, K., Ahn, M., Yu, C., Kim, S., Lin, M., Sriuranpong, V., et al. (2014). ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Annals of Oncology, 25(4), iv426–iv470. doi:10.1093/annonc/mdu349.
39. Kaneda, H., Okamoto, I., & Nakagawa, K. (2013). Rapid response of brain metastases to crizotinib in a patients with ALK rearrangement-positive non-small-cell lung cancer. Journal of Thoracic Oncology, 8(4), e32–33.
40. Kinoshita, Y., Koga, Y., Sakamoto, A., & Hidaka, K. (2013). Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Report. doi:10.1136/bcr-2013-200867.
41. Peled, N., Zach, L., Liran, O., Ilouze, M., Bunn, P. A., Jr., & Hirsch, F. R. (2013). Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. Journal of Thoracic Oncology, 8(12), e112–e113.
42. Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Yoshida, H., Yagi, Y., et al. (2013). High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. Journal of Thoracic Oncology, 8(9), e85–86.
43. Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W. L., Shen, Z., Tan, W., et al. (2011). CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. Journal of Clinical Oncology, 29(15), e443–e445.
44. Chun, S. G., Choe, K. S., Iyengar, P., Yordy, J. S., & Timmerman, R. D. (2012). Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biology and Therapy, 13(14), 1376–1383.
45. Gainor, J. F., Ou, S. H., Logan, J., Borges, L. F., & Shaw, A. T. (2013). The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology, 8(12), 1570–1573.
46. Metro, G., Lunardi, G., Floridi, P., Pascali, J. P., Marcomigni, L., Chiari, R., et al. (2015). CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. Journal of Thoracic Oncology, 10(5), e26–27.
47. Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., et al. (2011). CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell, 19(5), 679–690.
48. Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., et al. (2014). Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Molecular Cancer Therapeutics, 13(12), 2910–2918.
49. Kodama, T., Tsukaguchi, T., Yoshida, M., Kondoh, O., & Sakamoto, H. (2014). Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Letters, 351(2), 215–221.
50. Bartels, A. L., Kortekaas, R., Bart, J., Willemsen, A. T., de Klerk, O. L., de Vries, J. J., et al. (2009). Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiology of Aging, 30(11), 1818–1824.
51. Ohe, Y., Nishio, M., Kiura, K., Seto, T., Nakagawa, K., Maemondo, M., et al. (2015). A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): updates on progression free survival (PFS) and safety results from AF001JP. J Clin Oncol, 33(supple; abstr 8061).
52. Ou, S. H., Klempner, S. J., Azada, M. C., Rausei-Mills, V., & Duma, C. (2015). Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management. Lung Cancer, 88(3), 355–359.
53. Seto, T., Hida, T., Nakagawa, K., Satouchi, M., Nishio, M., Hotta, K., et al. (2014). Anti-tumor activity of alectinib in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study. Annals of Oncology, 25(4), iv426–iv470. doi:10.1093/annonc/mdu349.
54. Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A. S., et al. (2014). The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discovery, 4(6), 662–673.
55. Gainor, J. F., Tan, D. S., De Pas, T., Solomon, B. J., Ahmad, A., Lazzari, C., et al. (2015). Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clinical Cancer Research, 21(12), 2745–2752.
56. Zykadia, C. (2014). US prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
57. Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., et al. (2015). PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell, 28(1), 70–81.
58. Horn, L., Infante, JR., Blumenschein, GR., Wakelee, HA., Arkenau, HT., Dukar, G., et al. (2014). A phase I trial of X-396, a novel inhibitor, in patients with advanced solid tumors. J Clin Oncol, 32:5s (supple; abstr 8030^).
59. Arkenau, HT., Sachdev, JC., Mita, MM., Dziadziuszko, R., Lin, CC., Yang, JCH., et al. (2015). Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Oncol, 33(supple; abstr 8063).
60. Gandara, D. R., Li, T., Lara, P. N., Kelly, K., Riess, J. W., Redman, M. W., et al. (2014). Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clinical Lung Cancer, 15(1), 1–6.
61. Takeda, M., Okamoto, I., & Nakagawa, K. (2013). Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. Journal of Thoracic Oncology, 8(5), 654–657.
62. Ou, S. H., Jänne, P. A., Bartlett, C. H., Tang, Y., Kim, D. W., Otterson, G. A., et al. (2014). Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Annals of Oncology, 25(2), 415–422.